Webinar: HPTN083 Injectable Cabotegravir for PrEP
![20200909 – Pre-Exposure Prophylaxis for HIV Prevention – HPTN083 – Title Slide](https://www.seaetc.com/wp-content/uploads/2020/09/20200909-Pre-Exposure-Prophylaxis-for-HIV-Prevention-HPTN083-Title-Slide.jpg)
Facilitated by Rachel Presti, MD, PhD
Washington University School of Medicine
September 9, 2020
Other Trainings
- Webinar: HIV Pre-Exposure Prophylaxis 2023
- Webinar: Implementation of Evidence-Based Interventions in HIV Prevention and Care: From Malawi to North Carolina
- Archived Session: HIV Prevention for Women in the South
- Webinar: Update on PrEP: Focus on the Medications
- Staying PrEPared: An Update on Injectable Pre-Exposure Prophylaxis
Objectives
- To understand the differences between currently approved PrEP and long acting injectable agents
- To describe the conduct and outcome of the HPTN 083 study
- To discuss advantages/disadvantages of currently available and soon to be available PrEP options
Presentation
Slides
![20200909 – Pre-Exposure Prophylaxis for HIV Prevention – HPTN083 – Title Slide](https://www.seaetc.com/wp-content/uploads/2020/09/20200909-Pre-Exposure-Prophylaxis-for-HIV-Prevention-HPTN083-Title-Slide.jpg)
Facilitated by Rachel Presti, MD, PhD
Washington University School of Medicine
September 9, 2020
Objectives
- To understand the differences between currently approved PrEP and long acting injectable agents
- To describe the conduct and outcome of the HPTN 083 study
- To discuss advantages/disadvantages of currently available and soon to be available PrEP options
Presentation
Slides
Other Trainings
- Webinar: HIV Pre-Exposure Prophylaxis 2023
- Webinar: Implementation of Evidence-Based Interventions in HIV Prevention and Care: From Malawi to North Carolina
- Archived Session: HIV Prevention for Women in the South
- Webinar: Update on PrEP: Focus on the Medications
- Staying PrEPared: An Update on Injectable Pre-Exposure Prophylaxis
![20200909 – Pre-Exposure Prophylaxis for HIV Prevention – HPTN083 – Title Slide](https://www.seaetc.com/wp-content/uploads/2020/09/20200909-Pre-Exposure-Prophylaxis-for-HIV-Prevention-HPTN083-Title-Slide.jpg)
Facilitated by Rachel Presti, MD, PhD
Washington University School of Medicine
September 9, 2020
Objectives
- To understand the differences between currently approved PrEP and long acting injectable agents
- To describe the conduct and outcome of the HPTN 083 study
- To discuss advantages/disadvantages of currently available and soon to be available PrEP options
Presentation
Slides
Other Trainings
- Webinar: HIV Pre-Exposure Prophylaxis 2023
- Webinar: Implementation of Evidence-Based Interventions in HIV Prevention and Care: From Malawi to North Carolina
- Archived Session: HIV Prevention for Women in the South
- Webinar: Update on PrEP: Focus on the Medications
- Staying PrEPared: An Update on Injectable Pre-Exposure Prophylaxis